An LNP-CRISPR gene editing drug demonstrates efficacy and safety in patients with hereditary angioedema following in vivo administration.
The Journal of allergy and clinical immunology, 154(2): 272-274 PMID 38925443 DOI 10.1016/j.jaci.2024.06.011
Abstract
This article has no abstract in PubMed.